Tabassum H Laz1, Mahbubur Rahman, Abbey B Berenson. 1. Center for Interdisciplinary Research in Women's Health and Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Abstract
BACKGROUND: Human papillomavirus (HPV) vaccine uptake among young adult women has been reported to be very low. The authors conducted this study to provide an update on HPV vaccine uptake among 18- to 26-year-old women. METHODS: The authors used the National Health Interview Survey 2010 data to estimate HPV vaccine coverage and their correlates. RESULTS: Overall, 22.7% of women initiated (≥1 dose) and 12.7% completed the vaccine (≥3 doses). Thus, about 56% of women who initiated the vaccine completed it. Multivariate logistic regression analyses showed that younger age, unmarried status, Papanicolaou test, influenza vaccine, lifetime vaccines, and HPV vaccine awareness were positively associated with receiving ≥1 and ≥3 doses. In addition, uninsured women were less likely to receive ≥1 dose (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.28-0.84), and blacks (OR, 0.48; 95% CI, 0.23-0.99) and women with a family income <100% of the federal poverty level (OR, 0.40; 95% CI, 0.21-0.73) were less likely to receive ≥3 doses. Furthermore, based on vaccine initiators, blacks were less likely than whites to complete the vaccine (OR, 0.29; 95% CI, 0.16-0.55). Two thirds of unvaccinated women were not interested in future vaccination. Among those who were interested, >76.4% preferred to receive it free or at a lower cost, whereas 20% would pay the full cost of the vaccine. CONCLUSIONS: One in 8 women completed the 3-dose HPV vaccine. Educational and vaccine financing programs are needed to improve the uptake among low-income minority women who are at increased risk for cervical cancer.
BACKGROUND:Human papillomavirus (HPV) vaccine uptake among young adult women has been reported to be very low. The authors conducted this study to provide an update on HPV vaccine uptake among 18- to 26-year-old women. METHODS: The authors used the National Health Interview Survey 2010 data to estimate HPV vaccine coverage and their correlates. RESULTS: Overall, 22.7% of women initiated (≥1 dose) and 12.7% completed the vaccine (≥3 doses). Thus, about 56% of women who initiated the vaccine completed it. Multivariate logistic regression analyses showed that younger age, unmarried status, Papanicolaou test, influenza vaccine, lifetime vaccines, and HPV vaccine awareness were positively associated with receiving ≥1 and ≥3 doses. In addition, uninsured women were less likely to receive ≥1 dose (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.28-0.84), and blacks (OR, 0.48; 95% CI, 0.23-0.99) and women with a family income <100% of the federal poverty level (OR, 0.40; 95% CI, 0.21-0.73) were less likely to receive ≥3 doses. Furthermore, based on vaccine initiators, blacks were less likely than whites to complete the vaccine (OR, 0.29; 95% CI, 0.16-0.55). Two thirds of unvaccinated women were not interested in future vaccination. Among those who were interested, >76.4% preferred to receive it free or at a lower cost, whereas 20% would pay the full cost of the vaccine. CONCLUSIONS: One in 8 women completed the 3-dose HPV vaccine. Educational and vaccine financing programs are needed to improve the uptake among low-income minority women who are at increased risk for cervical cancer.
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Jessica A Kahn; Susan L Rosenthal; Yan Jin; Bin Huang; Azadeh Namakydoust; Gregory D Zimet Journal: Obstet Gynecol Date: 2008-05 Impact factor: 7.661
Authors: F Xavier Bosch; Ann N Burchell; Mark Schiffman; Anna R Giuliano; Silvia de Sanjose; Laia Bruni; Guillermo Tortolero-Luna; Susanne Kruger Kjaer; Nubia Muñoz Journal: Vaccine Date: 2008-08-19 Impact factor: 3.641
Authors: Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Suzanne M Garland; Diane M Harper; Grace W K Tang; Daron G Ferris; Marc Steben; Ronald W Jones; Janine Bryan; Frank J Taddeo; Oliver M Bautista; Mark T Esser; Heather L Sings; Micki Nelson; John W Boslego; Carlos Sattler; Eliav Barr; Jorma Paavonen Journal: Lancet Date: 2007-05-19 Impact factor: 79.321
Authors: Suzanne M Garland; Marc Steben; Heather L Sings; Margaret James; Shuang Lu; Radha Railkar; Eliav Barr; Richard M Haupt; Elmar A Joura Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: James L Klosky; Brianne Favaro; Kelly R Peck; Jessica L Simmons; Kathryn M Russell; Daniel M Green; Melissa M Hudson Journal: J Cancer Surviv Date: 2015-11-16 Impact factor: 4.442
Authors: James L Klosky; Melissa M Hudson; Yanjun Chen; James A Connelly; Karen Wasilewski-Masker; Can-Lan Sun; Liton Francisco; Laura Gustafson; Kathryn M Russell; Gina Sabbatini; Jessica S Flynn; Jocelyn M York; Anna R Giuliano; Leslie L Robison; F Lennie Wong; Smita Bhatia; Wendy Landier Journal: J Clin Oncol Date: 2017-08-24 Impact factor: 44.544
Authors: Angela K Shen; Michael J O'Grady; Roland D McDevitt; Jeremy D Pickreign; Laura K Laudenberger; Allahna Esber; Emily F Shortridge Journal: Public Health Rep Date: 2014 Jan-Feb Impact factor: 2.792
Authors: Abbey B Berenson; Eneida Male; Toy G Lee; Alan Barrett; Kwabena O Sarpong; Richard E Rupp; Mahbubur Rahman Journal: Am J Obstet Gynecol Date: 2013-11-23 Impact factor: 8.661
Authors: Jose-Miguel Yamal; Martial Guillaud; E Neely Atkinson; Michele Follen; Calum MacAulay; Scott B Cantor; Dennis D Cox Journal: Stat Anal Data Min Date: 2015-04-08 Impact factor: 1.051